Radius Health (RDUS) Osake Kurssi
Radius Health Kurssi
Viimeisten 19 vuoden aikana Radius Healthn liikevaihto kasvoi 6,3 % vuodessa ja ylsi 2,74 Mrd. USD:een. Osakekohtainen tulos on kasvanut 1,5 % vuodessa viimeisten 17 vuoden aikana. Radius Healthn nettomarginaali −9,7 % on laskenut verrattuna −0,2 %:iin muutama vuosi sitten. Nykyhinnalla osinkotuotto on noin 2,50 %. Osinko on kasvanut 13,5 % vuodessa viimeisten 19 vuoden aikana. Radius Healthn 12 kuukauden konsensustavoitehinta on 18,36 USD, noin ali kurssia 38,8 %. 8 analyytikosta 0 suosittaa ostoa — kokonaiskonsensus on Pidä.
Radius Health osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Radius Health liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Radius Health -osakkeesta
The business model of Radius Health Inc revolves around developing and commercializing innovative therapeutics to address unmet medical needs in the field of osteoporosis and other endocrine-related diseases. The company focuses on researching, developing, and marketing solutions that target the underlying causes of these conditions. By utilizing its expertise in hormone biology and technology platforms, Radius Health aims to provide patients with effective treatments that improve their overall health and quality of life. With a focus on delivering value and advancing scientific understanding, Radius Health Inc aims to be a leading player in the pharmaceutical industry.
Radius Health Inc is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Radius Health Inc in the market include pharmaceutical companies such as Amgen Inc, Eli Lilly and Company, and Novartis AG.
Radius Health Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapeutics in the field of osteoporosis and oncology. Founded in 2003, Radius Health Inc has established itself as a leader in the bone health market. The company's flagship product, TYMLOS®, is an FDA-approved therapy for postmenopausal women at high risk for fracture. With a strong team of experienced professionals and a robust pipeline of potential future treatments, Radius Health Inc continues to strive towards improving patient outcomes and addressing unmet medical needs in the areas of bone health and oncology.
Radius Health Inc has achieved significant milestones in its history. Some notable achievements include gaining FDA approval for their osteoporosis treatment drug, Tymlos, which has shown promising results in clinical trials. The company has also successfully expanded its market presence, solidifying partnerships with well-established pharmaceutical companies. Additionally, Radius Health Inc has made advancements in its research and development efforts, focusing on enhancing their product pipeline. These achievements demonstrate the company's commitment to providing innovative solutions for patients' healthcare needs.
Radius Health Inc is primarily present in the United States.
Radius Health Inc is a pharmaceutical company that is committed to improving the health and well-being of patients. With a strong corporate philosophy focused on innovation, research, and collaboration, Radius Health Inc strives to bring innovative and effective treatment options to the market. The company is dedicated to improving patient outcomes and providing value for both patients and shareholders. Through its dedication to research and development, Radius Health Inc aims to make a positive impact in the healthcare industry and contribute to the advancement of medical science.
Analyytikot asettavat tällä hetkellä Radius Health-osakkeelle keskimääräisen tavoitehinnan 18,36 USD (mediaani: 18,36 USD), mikä merkitsee −38,8 % viimeisimpään hintaan verrattuna. Konsensus perustuu 8 analyytikkoarvioon.
7 analyytikkoa arvioi tällä hetkellä Radius Health-osaketta: 0 suosittaa ostoa, 4 pitoa ja 3 myyntiä. Vuodelle 2026 analyytikot odottavat Radius Health-yhtiöltä 3,03 Mrd. USD liikevaihtoa ja 0,37 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Radius Health-osake noteerataan hintaan 26,92 EUR (30,00 USD).
Radius Health-osake (RDUS) on listattuna 4 pörssissä, muun muassa: NASDAQ (RDUS), SIX (Zürich) (1R8.SW), Frankfurt (1R8.F), Düsseldorf (1R8.DU).
Radius Health Inc is a pharmaceutical company that specializes in researching, developing, and marketing medications for the prevention and treatment of osteoporosis. The company was founded in 2003 and is headquartered in Waltham, Massachusetts, USA. The business model of Radius Health includes three main divisions: research and development, sales and marketing, and partnerships and licensing. In the area of research and development, the company continuously works on developing new medications that meet the needs of patients with osteoporosis and other bone diseases. The latest scientific methods are used to deepen the understanding of these diseases and their causes. On the other hand, the sales and marketing department of Radius Health is responsible for bringing the already developed medications into the market. The company works closely with doctors, hospitals, and other healthcare facilities to ensure that the medications are used correctly by patients. In addition, public relations efforts are made to raise awareness of osteoporosis and other bone diseases and to emphasize the importance of preventive measures. The third division of Radius Health deals with partnerships and licensing. The company collaborates with other pharmaceutical companies and research institutions to create synergies and share research findings. The company also licenses its already developed medications to other companies for sale in specific markets. An important component of Radius Health's business model is the products it offers. The company's most well-known medication is TYMLOS, which contains the active ingredient Abaloparatide. By specifically targeting bone metabolism, TYMLOS can help reduce the risk of fractures in women with postmenopausal osteoporosis. Another product is the preparation BAQSIMI, which is used to treat severe hypoglycemic shock in diabetes patients. In summary, Radius Health's business model is focused on developing and bringing to market innovative and effective medications for the prevention and treatment of osteoporosis. Through targeted research and development, intensive sales and marketing efforts, and partnerships and licensing, the company aims to strengthen awareness of bone diseases, improve patients' quality of life, and become a leading company in the industry.
odotettu liikevaihto Radius Health on 3,03 Mrd. USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Radius Health on 10,66 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Radius Health:n hinta-voitto-suhde (P/E) on tällä hetkellä 80,44. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Radius Health-osakkeen arvostusta.
Radius Health:n hinta-myynti-suhde (P/S) on tällä hetkellä 0,28. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Radius Health-osakkeen arvostuskennuslukuna.
Radius Health:n Eulpool-laatuscore on 1/10.
Radius Health:n ISIN on US7504692077. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Radius Health:n WKN on A114VH. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.
Radius Health:n ticker on RDUS. Tämä pörssinoteeraus käytetään Radius Health-osakkeiden kauppaan pörssissä.
Radius Health osake
Radius Health vertaisryhmä
Radius Health Ticker
Radius Health FIGI
Kaikki tunnusluvut ja syvällinen analyysi Radius Health:sta
Meidän osakeanalyysimme Radius Health-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Radius Health:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: